R.W. Roge & Company’s Eli Lilly LLY Stock Holding History

R.W. Roge & Company’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$563K	Buy	470 +3	+0.6%	+$3.06K	0.24%	40
2026 Q1	$429K	Sell	467 -186	-28%	-$189K	0.2%	43
2025 Q4	$701K	Buy	653 +103	+19%	+$98.5K	0.35%	37
2025 Q3	$419K	Hold	550	–	–	0.21%	38
2025 Q2	$428K	Hold	550	–	–	0.24%	36
2025 Q1	$454K	Sell	550 -3	-0.5%	-$2.5K	0.25%	34
2024 Q4	$426K	Hold	553	–	–	0.23%	30
2024 Q3	$489K	Buy	553 +3	+0.5%	+$2.7K	0.26%	29
2024 Q2	$497K	Hold	550	–	–	0.28%	28
2024 Q1	$428K	Hold	550	–	–	0.26%	31
2023 Q4	$320K	Hold	550	–	–	0.21%	35
2023 Q3	$308K	Hold	550	–	–	0.23%	35
2023 Q2	$257K	Buy	+550	New	+$231K	0.18%	35
2023 Q1	–	Sell	-550	Closed	-$201K	–	46
2022 Q4	$201K	Buy	+550	New	+$195K	0.13%	38

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

R.W. Roge & Company's LLY Position: Q2 2026 in Review

R.W. Roge & Company increased its Eli Lilly (LLY) stake by 0.64% in Q2 2026, buying an estimated $3.06K and bringing the position to 470 shares worth $563K. The position accounts for 0.24% of the portfolio, ranked #40.

R.W. Roge & Company first reported a position in LLY in Q4 2022 and has held it in 14 quarters since. The position peaked at $701K in Q4 2025. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

R.W. Roge & Company held 470 shares of Eli Lilly worth $563K as of Q2 2026.
R.W. Roge & Company bought 3 Eli Lilly shares in Q2 2026, an estimated $3.06K.
Eli Lilly made up 0.24% of R.W. Roge & Company's portfolio in Q2 2026, its #40 holding.
R.W. Roge & Company first reported a position in Eli Lilly in Q4 2022 and has held it in 14 quarters since.
R.W. Roge & Company's Eli Lilly position peaked at $701K in Q4 2025.
4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on R.W. Roge & Company's 13F filing for Q2 2026, filed 3 Aug 2026.